Convert VitaFOXO VITAFOXO to Resupply USD REUSD

This project will design a new RNA therapeutic that nudges the longevity-linked FOXO3 gene into its health-promoting form to halt the tissue breakdown behind degenerative disc disease—opening a precise, scalable route to drugs that extend healthspan. Dr. Lorna Harries’ lab has identified an innovative way to modulate FOXO3, a well known and yet undrugged longevity target, and propose leveraging it to address chronic lower back pain stemming from degenerative disc disease. They plan to make short, lab-made modified RNA molecules (antisense oligonucleotides) that selectively switch FOXO3’s “good” message on, first in human cells and mini-disc models. Success would yield 1) a lead drug candidate, 2) proof it can restore disc health, and 3) the data needed for patenting and further development. The same molecules could later be adapted to treat many other age-related conditions, helping people stay healthy for longer.

A decentralized stablecoin backed by Collateralized Debt Positions (CDP), leveraging the liquidity and stability of lending markets. The Resupply stablecoin is backed by other stablecoins that are earning interest on other lending markets. Designed to maximize yield returns by having the borrow rate always be half the lending rate being earned, half the risk-free rate, or two percent, whichever is greater. Emissions are designed for long-term sustainability by directing at three groups: the insurance pool, voting incentives, and directly at borrowers. The revenue that borrowers generate will directly correlate with the emissions directed towards them. The more revenue a borrower generates for Resupply, the greater the share of emissions it will receive. Targeted platforms for launch are Curve Lend and Fraxlend.